Rajeev M. Shah
CIK 1619841 · last filed 2026-06-11
Rajeev M. Shah is a corporate insider who has filed 106 SEC Form 4 insider transactions across 39 companies since 2016. The most recent filing, for PBLS, was dated Jun 11, 2026. Across all open-market trades the lifetime net is +$2.41B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.29B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.29B
39
106
$2.41B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBLS | Director | — | — | — | $0 | 1 | 2026-06-11 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 2,866,375 | $5.11 | $14.65M | $5.28M | 6 | 2026-06-08 |
| ACRV | Director | 9,366 | $1.48 | $13.9K | $211.84M | 2 | 2026-05-20 |
| COAG | Director | 6,372,170 | — | — | $313.97M | 2 | 2026-05-14 |
| ACET | 10%+ Owner | 932,624 | $8.05 | $7.51M | $0 | 1 | 2026-04-29 |
| PRLD | 10%+ Owner | 6,475,882 | $4.49 | $29.08M | $0 | 1 | 2026-04-28 |
| VOR | Director | 3,936,436 | $14.36 | $56.53M | -$82.92M | 4 | 2026-04-10 |
| ABOS | Director | 19,103,785 | $2.37 | $45.28M | $350.00M | 4 | 2026-03-18 |
| SGP | Director | 2,054,678 | $18.44 | $37.89M | $295.20M | 1 | 2026-02-11 |
| FULC | 10%+ Owner | 8,852,079 | $3.45 | $30.54M | -$233.41M | 2 | 2025-12-10 |
| WVE | Director | 28,815 | $5.87 | $169.1K | $20.00M | 3 | 2025-08-13 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 3,365,523 | $221.38 | $745.06M | $400.00M | 2 | 2025-06-30 |
| SPRY | Director | 902,904 | $9.76 | $8.81M | $116.25M | 3 | 2025-06-27 |
| TYRA | Director | 10,127,311 | $26.99 | $273.34M | $8.32M | 1 | 2025-06-16 |
| NKTX | Director | 754,311 | $2.86 | $2.16M | $0 | 2 | 2025-06-09 |
| HOWL | Director | 6,021,969 | $0.38 | $2.29M | $112.20M | 2 | 2025-05-14 |
| JANX | Director | 10,031,081 | $13.56 | $136.02M | $326.71M | 2 | 2025-03-07 |
| 89bio, Inc. (ETNB) Delisted | Director | 4,965,769 | $14.84 | $73.69M | $31.91M | 5 | 2024-11-18 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | 0 | $1.10 | $0 | $20.00M | 5 | 2023-06-08 |
| BDTX | Director | 311,926 | $1.75 | $545.9K | $19.00M | 7 | 2023-05-17 |
| MLYS | Director | — | $23.62 | — | $0 | 1 | 2023-02-13 |
| CTKB | Director | 12,459,692 | $3.96 | $49.34M | $69.40M | 2 | 2022-03-11 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 987,244 | $93.80 | $92.60M | $195.00M | 1 | 2021-07-06 |
| SLDB | Director | 11,580,287 | $7.14 | $82.68M | $66.75M | 10 | 2021-06-21 |
| KALA | Director | 10,914,613 | $2.63 | $28.71M | $78.00M | 8 | 2021-06-21 |
| PHAT | 10%+ Owner | 3,115,008 | $10.37 | $32.30M | -$124.25M | 1 | 2021-03-15 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 11,651,597 | $0.03 | $349.5K | $0 | 1 | 2021-02-08 |
| DYN | 10%+ Owner | 2,805,045 | $18.19 | $51.02M | $37.62M | 1 | 2020-09-23 |
| TGTX | 10%+ Owner | 12,629,868 | $49.52 | $625.43M | -$12.28M | 1 | 2020-09-11 |
| INBX | 10%+ Owner | 2,129,003 | $92.20 | $196.29M | $0 | 1 | 2020-08-24 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,417,259 | $10.15 | $44.84M | $81.22M | 1 | 2020-07-29 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 1,403,653 | $4.00 | $5.61M | $28.80M | 1 | 2020-07-28 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 1,408,912 | $60.05 | $84.61M | $19.50M | 1 | 2020-07-22 |
| RYTM | 10%+ Owner | 5,210,088 | $88.38 | $460.47M | -$25.47M | 2 | 2020-07-02 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | Director | 1,103,847 | — | — | $18.00M | 4 | 2020-05-29 |
| VSTM | 10%+ Owner | 17,303,351 | $4.10 | $70.94M | -$12.01M | 1 | 2020-04-29 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 0 | — | — | $32.70M | 7 | 2020-04-03 |
| IMRA | 10%+ Owner | 1,454,348 | $17.02 | $24.75M | $40.00M | 1 | 2020-03-17 |
| KALV | Director | 1,441,070 | $27.00 | $38.91M | $7.22M | 4 | 2017-10-16 |
Recent Filings
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | PBLS | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | ACRV | Grant (A) | +46,830 | $0 | EDGAR |
| 2026-05-14 | COAG | Buy (P) | +25,548 | $636.1K | EDGAR |
| 2026-05-06 | COAG | Mixed | +46,071,090 | $313.34M | EDGAR |
| 2026-04-29 | ACET | Other (J) | −1,000,000 | $0 | EDGAR |
| 2026-04-29 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-04-28 | PRLD | Other (J) | −5,628,000 | $0 | EDGAR |
| 2026-04-10 | VOR | Sell (S) | −2,480,532 | -$40.94M | EDGAR |
| 2026-03-18 | ABOS | Grant (A) | +30,303,030 | $100.00M | EDGAR |